Advances in stem cell biology, tissue engineering, and microphysiological systems are creating new opportunities for cardiovascular drug discovery and safety pharmacology. Among the more exciting developments are three-dimensional (3D) cardiac models, including cardiac organoids and engineered heart tissues, that seek to reproduce aspects of human cardiac biology beyond what is possible with traditional cell culture systems.

At CorDynamics, we are actively exploring this emerging field, engaging with technology developers, and evaluating the potential applications of these platforms in cardiovascular research.

A New Level of Biological Complexity

Traditional cell-based cardiac assays have long played an important role in drug discovery, particularly in evaluating ion channel activity, electrophysiology, and potential cardiotoxicity. However, advances in 3D tissue engineering are making it possible to study increasingly complex cellular interactions and functional responses.

Emerging platforms can incorporate multiple cardiac cell types, including cardiomyocytes, fibroblasts, endothelial cells, and other supporting populations, within organized tissue structures.

Depending on the technology, these systems may exhibit coordinated electrical activity, rhythmic contraction, and structural features that more closely approximate aspects of native cardiac tissue.

Potential applications extend beyond conventional cardiotoxicity screening to include assessment of cardiac contractility, arrhythmia mechanisms, myocardial injury, disease modeling, and responses to novel therapeutic modalities.

From Technological Innovation to Practical Application

While the progress is impressive, many of these technologies remain in the characterization and validation phases.

Important questions remain regarding the maturity of the cardiac tissue, reproducibility across experiments, pharmacological responsiveness, and the relationship between experimental findings and clinical cardiovascular effects.

Different platforms also offer different capabilities. Some emphasize structural complexity and cellular interactions, while others prioritize functional measurements such as contractile force or electrophysiological activity.

Understanding these distinctions will be important in determining where individual technologies can provide the greatest scientific value.

We are particularly interested in how these platforms perform when challenged with well-characterized pharmacological agents and whether they can provide meaningful information beyond that available from existing experimental approaches.

CorDynamics’ Perspective

With more than two decades of experience in cardiovascular drug discovery and safety pharmacology, CorDynamics recognizes the importance of continually evaluating technologies that may improve the quality and translational relevance of preclinical research.

We see considerable potential for 3D cardiac systems to contribute to earlier identification of cardiovascular liabilities, improved mechanistic understanding, and more informed drug development decisions.

Our current focus is on understanding the capabilities and limitations of these emerging platforms and identifying opportunities where they may provide meaningful scientific value.

As the field continues to mature, CorDynamics intends to remain actively engaged in evaluating these technologies and their potential integration into cardiovascular drug development programs.

We look forward to the continued evolution of this exciting area of cardiovascular research.

 

About CorDynamics

CorDynamics is the only CRO dedicated to answering your cardiovascular toxicology and safety pharmacology questions for your lead compound today—rather than reacting tomorrow.